SG11202107966TA - Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors - Google Patents

Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors

Info

Publication number
SG11202107966TA
SG11202107966TA SG11202107966TA SG11202107966TA SG11202107966TA SG 11202107966T A SG11202107966T A SG 11202107966TA SG 11202107966T A SG11202107966T A SG 11202107966TA SG 11202107966T A SG11202107966T A SG 11202107966TA SG 11202107966T A SG11202107966T A SG 11202107966TA
Authority
SG
Singapore
Prior art keywords
treating
fusion proteins
extracellular domain
negative tumors
tumors
Prior art date
Application number
SG11202107966TA
Inventor
Susannah D Barbee
Thomas Brennan
Barbara Sennino
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of SG11202107966TA publication Critical patent/SG11202107966TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
SG11202107966TA 2019-02-22 2020-02-21 Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors SG11202107966TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809319P 2019-02-22 2019-02-22
US201962815249P 2019-03-07 2019-03-07
PCT/US2020/019135 WO2020172482A2 (en) 2019-02-22 2020-02-21 Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors

Publications (1)

Publication Number Publication Date
SG11202107966TA true SG11202107966TA (en) 2021-09-29

Family

ID=70057229

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107966TA SG11202107966TA (en) 2019-02-22 2020-02-21 Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors

Country Status (10)

Country Link
US (1) US20220031806A1 (en)
EP (1) EP3927365A2 (en)
JP (1) JP2022521299A (en)
KR (1) KR20210130706A (en)
AU (1) AU2020224137A1 (en)
CA (1) CA3130752A1 (en)
MX (1) MX2021010061A (en)
SG (1) SG11202107966TA (en)
TW (1) TW202045544A (en)
WO (1) WO2020172482A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6936221B2 (en) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド CD80 extracellular domain polypeptides and their use in cancer treatment
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
EP4054721A1 (en) * 2019-11-04 2022-09-14 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
CN112326961B (en) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 Analysis method and storage device for proportion of PD-L1 positive tumor cells in non-small cell lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1638941T1 (en) 2003-05-22 2010-11-30 Abbott Lab Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2016007235A1 (en) * 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
JP6936221B2 (en) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド CD80 extracellular domain polypeptides and their use in cancer treatment

Also Published As

Publication number Publication date
EP3927365A2 (en) 2021-12-29
TW202045544A (en) 2020-12-16
JP2022521299A (en) 2022-04-06
WO2020172482A2 (en) 2020-08-27
US20220031806A1 (en) 2022-02-03
KR20210130706A (en) 2021-11-01
AU2020224137A1 (en) 2021-10-14
CA3130752A1 (en) 2020-08-27
WO2020172482A3 (en) 2020-10-01
MX2021010061A (en) 2021-12-10

Similar Documents

Publication Publication Date Title
SG11202107966TA (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
ZA202100125B (en) Novel fusion protein specific for cd137 and pd-l1
IL285702A (en) Heterocyclic amides useful as protein modulators
GB201818962D0 (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
IL262094A (en) Heterocyclic amides useful as protein modulators
EP3223730A4 (en) Method and apparatus for joint fusion
SI3532036T1 (en) Process for isolating and lyophilizing extracellular vesicles
EP3491286A4 (en) Artificial light compensation system and process
EP3610192A4 (en) Hybrid lens for controlled backlight distribution
EP3527980A4 (en) Method for recovering extracellular vesicles
EP3225690A4 (en) Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use thereof
IL278016A (en) Method for enhancing the suppressive properties of treg cells
EP3660143A4 (en) Method for isolating extracellular vesicle using hydrophobic interaction
EP3461506A4 (en) Material for intraocular lenses
IL281003A (en) Cd80 extracellular domain fc fusion protein dosing regimens
EP3191000A4 (en) Guidance system and method for bone fusion
SG11202000775SA (en) Fusion tags for recombinant protein expression
GB201714890D0 (en) Method and system for identifying membrane proteins on extracellular vesicles
EP3869177A4 (en) Method for recovering extracellular vesicles
EP3619564A4 (en) Light system for supplying light
IL281397B (en) Human pd-l1 antibodies
EP3139955A4 (en) Fusion proteins for treating cancer and related methods
EP3730603A4 (en) Method for stabilizing extracellular vesicles
EP3925979A3 (en) Fgfr-tacc fusion proteins and methods thereof
IL266183B (en) Fused azaheterocyclic compounds and their use as ampa receptor modulators